Search Results

Oryzon Genomics, S.A. announced the voting results from its Annual General Meeting of Shareholders held in Madrid.

Oryzon Genomics, S.A announced today that its management will give an update on corporate progress at several international events in June.

Oryzon Genomics, S.A. announced that the European Patent Office has issued an “intention to grant” communication for Oryzon’s European patent application EP18748921.6 entitled “Methods of treating behavior alterations” related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders like borderline personality disorder and schizophrenia.

Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events in April.